280 related articles for article (PubMed ID: 33569568)
1. Longitudinal Course of Agitation and Aggression in Patients with Alzheimer's Disease in a Cohort Study: Methods, Baseline and Longitudinal Results of the A3C Study.
De Mauleon A; Delrieu J; Cantet C; Vellas B; Andrieu S; Rosenberg PB; Lyketsos CG; Soto Martin M
J Prev Alzheimers Dis; 2021; 8(2):199-209. PubMed ID: 33569568
[TBL] [Abstract][Full Text] [Related]
2. Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria.
De Mauleon A; Ismail Z; Rosenberg P; Miller D; Cantet C; O'Gorman C; Vellas B; Lyketsos C; Soto M
Alzheimers Dement; 2021 Oct; 17(10):1687-1697. PubMed ID: 34132461
[TBL] [Abstract][Full Text] [Related]
3. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
Rosenberg PB; Drye LT; Porsteinsson AP; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Weintraub D; Newell J; Yesavage J; Lyketsos CG;
Int Psychogeriatr; 2015 Dec; 27(12):2059-67. PubMed ID: 26305876
[TBL] [Abstract][Full Text] [Related]
4. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
[TBL] [Abstract][Full Text] [Related]
5. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease.
Herrmann N; Ruthirakuhan M; Gallagher D; Verhoeff NPLG; Kiss A; Black SE; Lanctôt KL
Am J Geriatr Psychiatry; 2019 Nov; 27(11):1161-1173. PubMed ID: 31182351
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease.
Herrmann N; Gauthier S; Boneva N; Lemming OM;
Int Psychogeriatr; 2013 Jun; 25(6):919-27. PubMed ID: 23472619
[TBL] [Abstract][Full Text] [Related]
7. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
Wilcock GK; Ballard CG; Cooper JA; Loft H
J Clin Psychiatry; 2008 Mar; 69(3):341-8. PubMed ID: 18294023
[TBL] [Abstract][Full Text] [Related]
8. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study.
Herrmann N; Cappell J; Eryavec GM; Lanctôt KL
CNS Drugs; 2011 May; 25(5):425-33. PubMed ID: 21476613
[TBL] [Abstract][Full Text] [Related]
9. Agitation and aggression in people living with dementia and mild cognitive impairment in shared-housing arrangements - validation of a German version of the Cohen-Mansfield Agitation Inventory-Short Form (CMAI-SF).
Kratzer A; Scheel-Barteit J; Altona J; Wolf-Ostermann K; Graessel E; Donath C
Health Qual Life Outcomes; 2023 May; 21(1):51. PubMed ID: 37248478
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis.
Ballard CG; Coate B; Abler V; Stankovic S; Foff E
Int J Geriatr Psychiatry; 2020 Nov; 35(11):1402-1408. PubMed ID: 32729631
[TBL] [Abstract][Full Text] [Related]
11. Potentially modifiable factors associated with agitation and aggression in Alzheimer's disease: results of the ICTUS study.
de Mauleon A; Soto M; Ousset PJ; Nourhashemi F; Lepage B; Vellas B
Int Psychogeriatr; 2019 Oct; 31(10):1509-1516. PubMed ID: 30714541
[TBL] [Abstract][Full Text] [Related]
12. 24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone.
Ruthirakuhan M; Herrmann N; Andreazza AC; Verhoeff NPLG; Gallagher D; Black SE; Kiss A; Lanctôt KL
J Alzheimers Dis; 2019; 71(1):21-31. PubMed ID: 31322567
[TBL] [Abstract][Full Text] [Related]
13. Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory. The Alzheimer's Disease Cooperative Study.
Koss E; Weiner M; Ernesto C; Cohen-Mansfield J; Ferris SH; Grundman M; Schafer K; Sano M; Thal LJ; Thomas R; Whitehouse PJ
Alzheimer Dis Assoc Disord; 1997; 11 Suppl 2():S45-50. PubMed ID: 9236952
[TBL] [Abstract][Full Text] [Related]
14. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
Forester B; Vanelli M; Hyde J; Perez R; Ahokpossi C; Sribney W; Adkison L
Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the Cohen-Mansfield agitation inventory with the CERAD behavioral rating scale for dementia in community-dwelling persons with Alzheimer's disease.
Weiner MF; Koss E; Patterson M; Jin S; Teri L; Thomas R; Thal LJ; Whitehouse P
J Psychiatr Res; 1998; 32(6):347-51. PubMed ID: 9844950
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial.
Fox C; Crugel M; Maidment I; Auestad BH; Coulton S; Treloar A; Ballard C; Boustani M; Katona C; Livingston G
PLoS One; 2012; 7(5):e35185. PubMed ID: 22567095
[TBL] [Abstract][Full Text] [Related]
17. Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer's dementia.
Van der Mussele S; Le Bastard N; Saerens J; Somers N; Mariën P; Goeman J; De Deyn PP; Engelborghs S
Aging Ment Health; 2015; 19(3):247-57. PubMed ID: 24962058
[TBL] [Abstract][Full Text] [Related]
18. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease.
Trzepacz PT; Cummings J; Konechnik T; Forrester TD; Chang C; Dennehy EB; Willis BA; Shuler C; Tabas LB; Lyketsos C
Int Psychogeriatr; 2013 May; 25(5):707-19. PubMed ID: 23257314
[TBL] [Abstract][Full Text] [Related]
19. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
20. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression.
Wang LY; Shofer JB; Rohde K; Hart KL; Hoff DJ; McFall YH; Raskind MA; Peskind ER
Am J Geriatr Psychiatry; 2009 Sep; 17(9):744-51. PubMed ID: 19700947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
